Shree Ganesh Biotech India Stock Hits 52-Week Low at Rs.0.61

Stock Price Movement and Market Context

On 28 Nov 2025, Shree Ganesh Biotech India’s stock price settled at Rs.0.61, establishing both a 52-week and all-time low. This price is notably below its 52-week high of Rs.1.19, reflecting a decline of nearly 49% from that peak. The stock is trading beneath all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating persistent downward momentum.

In comparison, the broader market has shown resilience. The Sensex opened flat but gained 0.24% to trade at 85,923.99, just 0.15% shy of its 52-week high of 86,055.86. The index is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average, signalling a positive market trend. Mega-cap stocks have been leading this upward movement, contrasting with the performance of Shree Ganesh Biotech India.

Financial Performance Overview

Over the past year, Shree Ganesh Biotech India’s stock has recorded a return of -42.06%, while the Sensex has shown a positive return of 8.70% over the same period. This divergence highlights the challenges faced by the company within the Pharmaceuticals & Biotechnology sector.

Net sales for the nine months ended September 2025 stood at Rs.5.16 crores, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the company reported a net loss after tax of Rs.0.61 crores for the same period, also down by 44.64%. These figures indicate a reduction in revenue and profitability.

Profitability and Debt Servicing Metrics

The company’s average return on equity (ROE) is 2.62%, suggesting limited profitability relative to shareholders’ funds. Additionally, the average EBIT to interest ratio is 0.91, which points to a constrained ability to cover interest expenses from operating earnings. This ratio below 1.0 typically signals pressure on debt servicing capacity.

Further, the debtors turnover ratio for the half-year period is recorded at 0.00 times, indicating potential issues in realising receivables efficiently. Negative earnings before interest, taxes, depreciation and amortisation (EBITDA) have also been noted, contributing to the perception of financial risk associated with the stock.

Shareholding and Sector Position

Shree Ganesh Biotech India operates within the Pharmaceuticals & Biotechnology industry and sector. The majority of its shareholding is held by non-institutional investors, which may influence liquidity and trading patterns. The stock’s performance contrasts with the sector’s general trend, as the broader Pharmaceuticals & Biotechnology sector has not mirrored the same level of decline.

Valuation and Risk Considerations

The stock is currently trading at levels considered risky relative to its historical valuations. Over the last year, profits have fallen by approximately 86.6%, underscoring the financial strain on the company. This decline in profitability, combined with the stock’s price movement, reflects a challenging environment for Shree Ganesh Biotech India.

Summary of Current Position

Shree Ganesh Biotech India’s stock reaching Rs.0.61 marks a significant low point in its trading history. The company’s financial data over recent periods shows contraction in sales and profitability, alongside challenges in debt servicing and receivables management. These factors have contributed to the stock’s subdued performance relative to the broader market and sector indices.

While the Sensex and mega-cap stocks have demonstrated positive momentum, Shree Ganesh Biotech India remains positioned at a lower valuation level, reflecting the ongoing pressures within its financial and operational framework.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →